Rob has more than 25 years of life sciences industry experience, beginning his career in academic and industry research and development before taking on roles in equity research, business development, strategic planning and consulting.
Rob is a life sciences leader with more than two decades of experience in academic, research and development and advisory roles. He has deep expertise in research technologies, genomics, immunology and diagnostics that he has applied to his work across therapeutic areas, with organizations ranging from startups to global pharmaceutical and diagnostic firms.
Rob brings a data-driven approach to helping life sciences organizations prepare for the future. Over the course of his career, Rob has helped leadership teams develop franchise and portfolio strategies, conduct landscape assessments and revenue forecasts, and benchmark early-stage development research trends to inform the product lifecycle.
Prior to joining Huron, Rob was a Principal at The Frankel Group, a life sciences strategy consultancy. Before that, he was director of business development and strategic planning at Transgenomic Inc., a genomics company that supports translational research, diagnostics and personalized medicine, with a significant oncology focus.
Rob began his career as a scientist, initially as a research fellow at the Mayo Clinic, and subsequently at Wyeth Vaccines as a senior research scientist. His research pursuits have included regulation of gene expression, molecular and cellular immunology, and gene therapy of the immune system.